Improved drug-target deconvolution with PISA-DIA using an extended, overlapping temperature gradient

ABSTRACT: For target-engagement applications, a comparative analysis was performed to assess the suitability, ease of implementation and cost-effectiveness between Cellular Thermal Shift Assay (CETSA) and Proteome Integral Solubility Alteration (PISA). Human multiple myeloma cells U266B1 cell lysate was treated with either 1 μM BCL-XL inhibitor or DMSO as a vehicle to perform i) label-free PISA approach to analyse each PISA pool by data-independent acquisition (DIA) approach (PISA-DIA-MS) and ii) traditional TMT labelled proteome-wide CETSA approach (CETSA-TMT-MS).

INSTRUMENT(S): Orbitrap Eclipse, timsTOF Pro

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Cell

DISEASE(S): Multiple Myeloma

SUBMITTER: Laura Dagley  

LAB HEAD: Dr. Laura Dagley

PROVIDER: PXD044545 | Pride | 2024-05-20

REPOSITORIES: Pride